China's National Joint Procurement Office Disqualifies Eugia Pharma and JSC "Farmak" Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules
Policy / Regulatory

China’s National Joint Procurement Office Disqualifies Eugia Pharma and JSC “Farmak” Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules

The National Joint Procurement Office for Drugs announced that two selected companies in China's national centralized drug procurement program have been disqualified and placed on the "violation list" after failing…

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line
CompanyDrug

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas
CompanyDrug

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma
CompanyDrug

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

FDA Approves Priovant's LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication
CompanyDrug

FDA Approves Priovant’s LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication

GenFleet's Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors
CompanyDrug

GenFleet’s Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte
CompanyDrug

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte

CSPC Pharmaceutical Initiates Phase II Trial of SYH2072 – Self‑Developed Aldosterone Synthase Inhibitor Targeting Uncontrolled and Refractory Hypertension in China
CompanyDrug

CSPC Pharmaceutical Initiates Phase II Trial of SYH2072 – Self‑Developed Aldosterone Synthase Inhibitor Targeting Uncontrolled and Refractory Hypertension in China

Boehringer Ingelheim Launches AIRWARD Phase III Trial of Verducatib – First Oral DPP1 Inhibitor to Reach Phase III in COPD
CompanyDrug

Boehringer Ingelheim Launches AIRWARD Phase III Trial of Verducatib – First Oral DPP1 Inhibitor to Reach Phase III in COPD

NMPA Grants Priority Review to Hengrui’s Trastuzumab Rezetecan NDA for First‑Line HER2‑Positive Breast Cancer

NMPA Grants Priority Review to Hengrui's Trastuzumab Rezetecan NDA for First‑Line HER2‑Positive Breast Cancer

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for a new indication of Trastuzumab rezetecan, with priority review granted. The application seeks approval for…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia
CompanyDeals

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia

Zuellig Pharma Acquires Licensed Pharmaceutical Entity and Facility in Hangzhou, China – Strategic Move Strengthens Clinical Trial Sourcing Capabilities
CompanyDeals

Zuellig Pharma Acquires Licensed Pharmaceutical Entity and Facility in Hangzhou, China – Strategic Move Strengthens Clinical Trial Sourcing Capabilities

Alfasigma Reclaims Sulodexide Rights in China – Business Transfer to Add €25 Million in Annual Revenue and Drive 30 % Expansion of Alfasigma China
CompanyDeals

Alfasigma Reclaims Sulodexide Rights in China – Business Transfer to Add €25 Million in Annual Revenue and Drive 30 % Expansion of Alfasigma China

Bayer Q3 2026 Sales Reach €10.053 Billion as Pharmaceuticals Division Hits Growth Turning Point – Nubeqa and Kerendia Lead the Rebound
Company

Bayer Q3 2026 Sales Reach €10.053 Billion as Pharmaceuticals Division Hits Growth Turning Point – Nubeqa and Kerendia Lead the Rebound

Lynk Pharmaceuticals Expands Commercialization Partnership with Simcere – Exclusive Greater China Rights for Zemprocitinib Extended to Atopic Dermatitis and Dermatological Indications
CompanyDeals

Lynk Pharmaceuticals Expands Commercialization Partnership with Simcere – Exclusive Greater China Rights for Zemprocitinib Extended to Atopic Dermatitis and Dermatological Indications

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full
CompanyDeals

Novartis Terminates BrainTransporter Collaboration with BioArctic – Program Discontinued, $30 Million Upfront Retained in Full

BioArctic AB (OTCMKTS: BRCTF) announced that Novartis AG (NYSE: NVS) has notified the company of its decision to terminate the Option, Collaboration and License Agreement entered into in August 2025.…

Jinhai Medical Signs Strategic Cooperation MOU with Digital Health China – Exploring Business Operations Collaboration and Equity Investment in Medical AI
CompanyDeals

Jinhai Medical Signs Strategic Cooperation MOU with Digital Health China – Exploring Business Operations Collaboration and Equity Investment in Medical AI

Fresenius Medical Care Inks Decade‑Long Biosimilar Partnership with WuXi Biologics – Rights to Up to 37 Candidates in Industry's Largest Deal of Its Kind
CompanyDeals

Fresenius Medical Care Inks Decade‑Long Biosimilar Partnership with WuXi Biologics – Rights to Up to 37 Candidates in Industry’s Largest Deal of Its Kind

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates
CompanyDeals

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal
CompanyDeals

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

- Advertisement -
Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

The Comprehensive Department of China's National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that…

China's National Joint Procurement Office Opens Information Change Channel for National VBP Selected Products – MAH Changes, Entrusted Manufacturer Adjustments and Supplementary Selection Now Permitted While Retaining Selected Status
Policy / Regulatory

New VBP Announcement Opens MAH Change and Supplementary Selection Channel – Paper Applications Due Before 30 October 2026 in Shanghai

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions
Policy / Regulatory

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added
Policy / Regulatory

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added

More News

Lifetech Scientific Wins CE MDR Certification for IBS Absorbable Drug‑Eluting Coronary Stent – World's First Iron‑Based Bioresorbable Coronary Stent Approved
CompanyMedical Device

Lifetech Scientific Wins CE MDR Certification for IBS Absorbable Drug‑Eluting Coronary Stent – World’s First Iron‑Based Bioresorbable Coronary Stent Approved

CSPC Reports Positive Top‑Line Phase III Data for Prusogliptin/Dapagliflozin/Metformin Triple Combination – Superior Glycemic Control in Type 2 Diabetes
CompanyDrug

CSPC Reports Positive Top‑Line Phase III Data for Prusogliptin/Dapagliflozin/Metformin Triple Combination – Superior Glycemic Control in Type 2 Diabetes

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion
Company

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS
CompanyDrug

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

BMS Q3 Revenue Rises 7% to USD 13.1 Billion as Eliquis Surges 25% and Growth Portfolio Climbs 12%; Full‑Year Outlook Raised
Company

BMS Q3 Revenue Rises 7% to USD 13.1 Billion as Eliquis Surges 25% and Growth Portfolio Climbs 12%; Full‑Year Outlook Raised

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D
CompanyDeals

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

MSD Q3 Revenue Rises 5% to USD 18.1 Billion as Keytruda Anchors Growth and China Pharmaceutical Sales Recover 14%
Company

MSD Q3 Revenue Rises 5% to USD 18.1 Billion as Keytruda Anchors Growth and China Pharmaceutical Sales Recover 14%

Junshi Biosciences Doses First Patient in Pivotal Phase III Trial of JS207 Plus JS007 Versus Toripalimab‑Bevacizumab in Advanced Hepatocellular Carcinoma
CompanyDrug

Junshi Biosciences Doses First Patient in Pivotal Phase III Trial of JS207 Plus JS007 Versus Toripalimab‑Bevacizumab in Advanced Hepatocellular Carcinoma

Show More